更新于：2024-11-01

Hemorrhagic Septicemia

出血性败血症

更新于：2024-11-01

基本信息

别名

Bacteremia, Hemorrhagic、Haemorrhagic Bacteremia、Haemorrhagic Septicaemia

+ [12]

简介

Any of several bacterial diseases, usually caused by PASTEURELLA MULTOCIDA, marked by the presence of hemorrhagic areas in the subcutaneous tissues, serous membranes, muscles, lymph glands, and throughout the internal organs. The diseases primarily affect animals and rarely humans.

关联

项与出血性败血症相关的药物

Avibactam Sodium/Ceftazidime

头孢他啶阿维巴坦钠

靶点

β-lactamase

作用机制

β-lactamase抑制剂

在研机构

Pfizer Manufacturing Ireland Unlimited Co. [+3]

原研机构

Allergan Ltd. (Ireland)

在研适应症

腹腔脓肿 [+15]

非在研适应症

急性肾盂肾炎 [+2]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2015-02-25

Biapenem

比阿培南

靶点

PBPs

作用机制

PBPs抑制剂

在研机构

Meiji Seika Pharma Co., Ltd. [+1]

原研机构-

在研适应症

膀胱炎 [+7]

非在研适应症

泌尿道感染

最高研发阶段批准上市

首次获批国家/地区-

首次获批日期2001-01-01

Teicoplanin

替考拉宁

靶点-

作用机制

细胞壁抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期1998-04-10

100 项与出血性败血症相关的临床结果

登录后查看更多信息

100 项与出血性败血症相关的转化医学

登录后查看更多信息

0 项与出血性败血症相关的专利（医药）

登录后查看更多信息

534

项与出血性败血症相关的文献（医药）

2024-12-01·Journal of Virological Methods

Development of a loop-mediated isothermal amplification (LAMP) assay for rapid and visual detection of Anguillid herpesvirus 1

Article

作者: Chen, Qiang ; Song, Tie-Ying ; Zhang, Li-Juan ; Ge, Jun-Qing

China has the largest aquaculture eel production in the world. High-density cultivation pattern often results in an outbreak of epidemic diseases. Since the 1990s, eel "mucus sloughing and hemorrhagic septicemia disease" was often broke out in China, and brought huge economic losses to eel breeders. Anguillid herpesvirus 1 (AngHV) was detected and isolated from the diseased eel, and proved to be the pathogen of the disease. In this study, a loop-mediated isothermal amplification (LAMP) assay was developed for rapid, sensitive, and specific detection of AngHV. A set of six primers targeting the ORF51 gene of AngHV was designed, which could effectively detect purified AngHV virions, AngHV-infected cells, or eel tissue samples. The suitable reaction temperature is 63℃, and the reaction time is 40 min. There was no cross-reaction with eel and other fish viruses, including Infectious pancreatic necrosis virus (IPNV), Marine birnavirus (MABV), Rana grylio virus (RGV), Cyprinid herpesvirus 3 (CyHV-3), and Eel iridovirus (EIV). The lower detection limit of the AngHV LAMP assay is 10 copies of AngHV genome DNA, which is at least 100 times more sensitive than conventional PCR in detecting AngHV. The assay could effectively detect AngHV from collected samples with typical clinical symptoms of AngHV infection. It suggested that the LAMP assay could be used in specific detection of AngHV and has great potential for early diagnosis of AngHV infection in the farm.

2024-11-01·Microbial Pathogenesis

Antimicrobial potential of carvacrol against Edwardsiella piscicida in vitro

Article

作者: Bingwen, Xi ; Xie, Jun ; Qin, Ting ; Pan, Liangkun ; Dowah, Richline Gedeh Wentee ; Xi, Bingwen ; Chen, Kai

With the alarming rise of antibiotic-resistant bacteria, novel antibacterial substances are urgently needed for controlling and treating multidrug-resistant bacterial infections. Edwardsiella piscicida is an important zoonotic enteric pathogen, that can cause systemic hemorrhagic septicemia in fish. Carvacrol, a major terpene of oregano essential oil, has a wide range of antibacterial activities. This study aimed to analyze the effect of carvacrol on the growth and virulence of E. piscicida in vitro. The minimum inhibitory concentration (MIC) of carvacrol against E. piscicida was 125 μg/mL. The sub-inhibitory concentrations of carvacrol significantly decreased the biofilm formation of E. piscicida in a dose dependent manner, whereas increased the hemolytic activity with a negative correlation. The quantitative real-time PCR results showed that carvacrol at sub-MICs downregulated the expression of related virulence genes, including flagellum (fimA, fliC, flgN), hemolysins (ethA, ethB), quorum sensing systems (luxR, qseB), T3SS (esrB, esrC) and T6SS (evpB, evpC). Moreover, carvacrol (≤1/8 MIC) reduced the cytotoxicity, adherence and internalization activities of E. piscicida to the EPC cells. In vivo trial, the diet mixed with carvacrol increased the survival of zebrafish infected with E. piscicida. Overall, these findings suggested that carvacrol might be a promising therapeutic agent against E. piscicida infection in aquaculture.

2024-11-01·Systematic and Applied Microbiology

Description of three new Pseudomonas species isolated from aquarium fish: Pseudomonas auratipiscis sp. nov., Pseudomonas carassii sp. nov. and Pseudomonas ulcerans sp. nov

Article

作者: Mulet, Magdalena ; Burcin Saticioglu, Izzet ; Lalucat, Jorge ; Gomila, Margarita ; Ajmi, Nihed ; García Valdés, Elena ; Altun, Soner ; García-Valdés, Elena ; Duman, Muhammed

Pseudomonas species constitute a significant group of pathogens in aquarium fish and frequently cause haemorrhagic septicaemia. This study conducted a taxonomic characterization of Pseudomonas isolates from aquarium fish exhibiting deep ulceration and general disease signs. A polyphasic approach was employed to ascertain the taxonomic affiliation of the strains. The overall genome relatedness indices of digital DNA-DNA hybridization (dDDH) and average nucleotide identity (ANI) between the strains and the other members of the genus Pseudomonas were found to be below the established thresholds of 70 and 95-96%, respectively. Whole-genome based phylogenetic analysis revealed that strains 119P^T and 120P were closely related to P. arcuscaelestis. Strain 137P^T was related to P. peradeniyensis, while strains 147P^T and 148P were closely related to P. japonica. The morphological, physiological, and biochemical characteristics of the strains and the genome relatedness indices of dDDH and ANI below the established thresholds confirmed the classification of the strains as three novel species. Genome analyses of the strains were also conducted to determine their biosynthesis-related gene clusters, virulence features and ecological distribution patterns. Based on polyphasic characterization, the strains 119P^T, 120P, 137P^T, 147P^T, and 148P are novel species within the genus Pseudomonas, for which the following names are proposed: Pseudomonas auratipiscis sp. nov., with the strain 119P^T as the type strain (=DSM 117162 ^T, =LMG 33381^T); Pseudomonas carassii sp. nov., with the strain 137P^T as the type strain (=DSM 117060^T, =LMG 33378^T); and Pseudomonas ulcerans sp. nov. 147P^T, as the type strain (=DSM 117163^T, =LMG 33377^T).

项与出血性败血症相关的新闻（医药）

2022-04-08

·医药观澜

盐野义新型抗生素在中国获批临床

中国国家药监局药品审评中心（CDE）官网公示，盐野义公司（Shionogi）5.1类新药注射用cefiderocol已获得临床试验默示许可，适用于在治疗选择有限的成人患者中由需氧革兰氏阴性病原体引起的感染。公开资料显示，这是一款新型铁载体头孢菌素类抗生素药物，已在海外获批多个适应症，包括用于治疗由革兰氏阴性菌造成的多种感染。抗生素耐药性（AMR）是一个急需解决的健康负担，它的发生与细菌产生超广谱β-内酰胺酶和碳青霉烯酶的耐药机制有关。由革兰氏阴性菌引发的感染对药物的耐药性正在逐步增强，如今更多革兰氏阴性病原体能够对多种抗生素产生耐药性，导致患者发病和死亡率的增加。因此，患者急需可以有效治疗耐药性细菌感染的新疗法。盐野义公司的cefiderocol（S-649266）是一款在研新型抗生素药物。根据该公司官网，该产品已在美国获批用于复杂尿路感染，包括肾盂肾炎和医院感染，以及没有或有限治疗选择的肺炎；在欧洲获批用于治疗选择有限的成年患者中由需氧革兰氏阴性菌引起的感染。公开资料显示，cefiderocol具有一种独特的机制，可以使药物穿过包括多种耐药性（MDR）菌株在内的革兰氏阴性菌病原体的细胞膜。这种独特机制的启发来自著名的“特洛伊木马”的故事。研究人员发现，当我们的身体受到急性感染时，免疫系统会在体内制造一个缺铁的环境，这就使得细菌不得不提高铁摄入量。这时，与铁元素结合的新型抗生素则乘虚而入，顺利通过细菌的层层防守，从内部将细菌杀死。这种机制可以使cefiderocol在细胞周质内达到一个较高的浓度，与受体顺利结合，并抑制细胞壁合成，还可以对抗包括金属β-及丝氨酸β-在内的β-内酰胺酶类。除此之外，该产品还显示出在体外针对包括抗碳青霉烯的不动杆菌在内的多种革兰氏阴性菌的良好效果。来自APEKS-cUTI和APEKS-NP和CRREDIBLE-CR这三项临床研究的数据表明，cefiderocol对以下类型由需氧革兰氏阴性菌引起的感染患者有效：复杂性尿路感染（cUTI）、医院获得性肺炎（HAP）、呼吸机相关性肺炎（VAP），以及由复杂腹腔内感染（cIAI）和皮肤及皮肤结构感染（SSSI）引起的败血症、菌血症等。其中一项研究纳入了由多重耐药病原体引起的革兰氏阴性感染患者。本次cefiderocol在中国获批开展临床试验，意味着该产品也即将在中国进入临床开发。公开资料显示，目前cefiderocol还在美国和欧洲开展3期临床试验，针对儿童患者因多重耐药革兰氏阴性菌引起的感染。希望cefiderocol在临床研究中进展顺利，早日为更多耐药性感染患者带来新的治疗选择。参考资料： [1] 中国国家药监局药品审评中心（CDE）官网.Retrieved Apr 7，2022, from https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d [2] 盐野义公司官网. from https://www.shionogi.com/global/en/innovation/pipeline.html[3]Shionogi Receives European Commission Marketing Authorisation for FETCROJA® (cefiderocol) for the Treatment of Infections Due to Aerobic Gram-negative Bacteria in Adults With Limited Treatment Options. Retrieved April 27, 2020 from https://www.businesswire.com/news/home/20200427005719/en/Shionogi-Receives-European-Commission-Marketing-Authorisation-FETCROJA%C2%AE 内容来源于网络，如有侵权，请联系删除，谢谢

创新药抗体